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ABSTRACT IN CZECH 
Léková závislost (dependence) jako specifický fenotyp idiopatických střevních zánětů (IBD), 
Crohnovy nemoci (CN) a ulcerózní kolitidy (UC), předurčuje prognózu onemocnění. Může být 
proto využit jako důležitý prognostický ukazatel při volbě optimálního terapeutického postupu. 
Dependence je dobře popsaná u IBD pacientů léčených kortikosteroidy a recentně byla také 
potvrzena u nemocných léčených infliximabem (IFX dependence). Cílem této práce bylo: 1) 
zhodnotit výskyt IFX dependence u dětských a dospělých pacientů s CN; dále identifikovat 
klinické a genetické prediktory odpovědi na IFX a zhodnotit vliv IFX dependence na frekvenci 
operací; 2) zhodnotit u pacientů s CN výsledky 5-ASA monoterapie s ohledem na výskyt 5-ASA 
dependence a identifikovat klinické prediktory odpovědi na 5-ASA.  
Zjistili jsme, že 66% dětských a 29% dospělých pacientů s CN se stalo IFX dependentními. 
Vysoká frekvence u dětí je v souladu s dříve publikovanými prácemi, zatímco naše výsledky 
naznačují nižší výskyt IFX dependence u dospělé populace. Perianální onemocnění a 
nepřítomnost střevní operace před zahájením IFX byly identifikovány jako prediktory pro vznik 
IFX dependence u dětí. U dospělých pacientů, 2 genetické varianty LTA c.207 A>G a CASP9 
c.93 C>T byli asociovány s IFX odpovědí. Dětští i dospělí pacienti se setrvalou odpovědí na IFX 
a také ti se vzniklou IFX dependencí měli po zahájení terapie signifikantně nižší počet operací 
než non-respondenti na podávání IFX.  
Třicet-jedna procent zkoumaných pacientů s CN bylo léčeno 5-ASA jako monoterapii. 
Z celkového počtu léčených 5-ASA vykazovalo 59% dlouhodobý efekt této terapie, přičemž 
36% z nich dosáhlo setrvalou odpověď a u 23% pacientů došlo ke vzniku 5-ASA dependence. 
Ženy měly lepší dlouhodobou odpověď než muži, zatímco delší trvání nemoci bylo spojeno se 
vznikem 5-ASA dependence. Tento výsledek spolu s nálezem nejnižší frekvence střevních 
operací u 5-ASA dependentních pacientů zřejmě souvisí s velmi mírným typem onemocnění u 
této skupiny nemocných.  
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ABSTRACT IN ENGLISH 
Drug dependency in inflammatory bowel disease (IBD), Crohn´s disease (CD) and ulcerative 
colitis (UC) is a specific disease phenotype which determines disease prognosis and hence may 
be used as a prognostic marker for treatment management. Drug dependency in IBD has been 
well described in corticosteroid treatment and recently also in infliximab (IFX) therapy. The 
aims of this thesis were: 1) to assess the occurrence of IFX dependency in paediatric and adult 
patients with CD; further to search for clinical and genetic predictors of IFX outcome and to 
evaluate the impact of IFX dependency on surgical rate; 2) to assess in CD patients the outcome 
of the first course of 5-ASA monotherapy with emphasis on 5-ASA dependency and to define 
clinical predictors of 5-ASA treatment outcome.  
We found that 66% of children and 29% of adults with CD became IFX dependent. The high 
frequency in paediatrics is in agreement with previously published studies, while the finding in 
adult patients indicates a lower rate of IFX dependency in the only study to date. Perianal disease 
and no bowel surgery prior to IFX start were predictive of IFX dependency in paediatric patients. 
In adult cohort, 2 genetic variants LTA c.207 A>G and CASP9 c.93 C>T were associated with 
IFX outcome, whereas no relevant clinical predictor was identified. We observed a significant 
decrease in surgical rates after IFX start both in prolonged responders and IFX dependent 
patients, in paediatrics and adults.  
Thirty-one percent of studied CD patients had monotherapy with 5-ASA. Of the patients treated 
with 5-ASA 59% were shown to have a long-term benefit from 5-ASA as prolonged responders 
(36%) or 5-ASA dependent (23%). Female gender was found to be associated with a better long-
term outcome, while longer disease duration was predicative of 5-ASA dependency. This 
together with an observation of the lowest surgical rate in 5-ASA dependent patients may 
suggest these individuals to have a very mild disease phenotype.  
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Inflammatory bowel diseases (IBD) including Crohn´s disease (CD) and ulcerative colitis (UC) 
are chronic inflammatory disorders of gastrointestinal tract (1). In approximately one third of 
patients the disease is complicated by extraintestinal manifestations involving mainly joints, 
skin, eyes and liver (1). The peak age-interval at diagnosis is 16-35 years and six to seven 
percent of newly diagnosed patients are children below 15 years of age (2;3). Although both 
diagnoses share many similarities they represent two different entities as to pathologicoanatomic 
presentation, clinical manifestation and probably also etiopathogenesis (1).  
CD is characterized by transmural, granulomatuos and segmental inflammation of 
gastrointestinal tract that may theoretically involve any part of the digestive tract from mouth to 
the anus (1). The most frequent localization of CD is terminal ileum and/or colon with 
approximately equal proportion of involvement (4). In about 10 to 15% of patients the disease is 
localized in proximal parts of the small bowel and the minority of patients has gastroduodenal or 
esophageal involvement (4). Special form of CD is perianal disease (about 30% of patients) 
presenting as perianal abscesses or fistulas. Clinical symptoms of CD are various and include 
abdominal pain of different quality, diarrhea, weight loss, fever and less frequently rectal 
bleeding (1).   
UC is characterized by chronic inflammation of colonic mucosa only, involving rectum and 
spreading continuously as far as up to cecum (1). The mucosal changes may vary from mild 
findings including edema and loss of vascular pattern to severe changes of large ulcers (1). Based 
on the extent of inflamed colon UC may be classified as proctitis (involving only rectum), left-
sided colitis (spreading up to splenic flexure) or extensive colitis (spreading beyond splenic 
flexure), with almost equal proportion of these localizations (5). In contrast to CD; clinical 
manifestation of UC is more uniform including diarrhea and/or tenesmus with or without rectal 
bleeding and mucus evacuation (1).   
Both diseases are medically incurable and the goal of the current therapy is to induce and 
maintain long-standing remission. In majority of patients the disease course is characterized by 
periods of remission altered by episodes of active disease (relapses) of various length, frequency 
and severity (1). Nevertheless, about 10-15% of patients experience chronic continuously active 
disease despite the medical therapy (6). The disease location in CD seems to be more or less 
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stable; however the extent of UC tends to progress or regress over the time in a proportion of 
patients (7). Transmural nature of inflammation in CD may lead to local bowel complications 
such as strictures and/or bowel perforation in form of abscesses or fistulas and the frequency of 
these complications increases with the disease duration (8).  As much as 70-80% of CD patients 
undergo intestinal surgery within 20 years after diagnosis, and about 30% of individuals require 
repetitive procedure (6;9;10). In UC, the cumulative probability of colectomy after 25 years of 
disease duration is 20-30%, and is the highest during the first year after diagnosis (4). 
Although several clinical, genetic and serological markers have been identified to predict 
individual disease course, their use in daily clinical practice is very limited and the disease 
course and behaviour still remain somewhat unpredictable (11-13). Interestingly, self managed 
treatment with mesalazine and infliximab reflecting the individual disease course has been 
recently and successfully carried out in patients with IBD using the web based treatment systems 
(14;15). Future studies are needed to assess the potential of this new treatment approach to 
change the natural disease course.  
 
1.1 Epidemiology 
The highest incidence of IBD has been reported in western countries, particularly Scandinavian 
states, United Kingdom and North America (3;16-19). According to the latest epidemiological 
studies from the west Europe and North America performed after 1990 the incidence of CD 
ranges from 6.3 to 20.2/10
5
 inhabitants; corresponding incidence of UC varies from 3.9 to 17/10
5
 
inhabitants (4). The incidence of CD and at least in some countries also of UC is still increasing, 
although a plateau or a decrease in incidence of UC had been observed in some European 
countries (20).   
So far, the limited epidemiologic data from Eastern Europe or Asia reported considerably lower 
incidence of both diseases suggesting east- west gradient of incidence of IBD. Nevertheless the 
epidemiologic studies from these countries are mainly old of date and some of lower 
methodological quality. Furthermore the “eastern” life style has been changing towards the 
“western” one and the diagnostics of the disease have been also improving. Finally, some newer 
studies from east Europe indicate a relatively high incidence of IBD (4;20).   
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Due to these reasons the multicenter epidemiologic study investigating the incidence of IBD 
across European countries, Israel and one Asian country has been started (Burisch J et al, 
accepted at DDW congress San Diego 2012 for poster presentation). Based on the preliminary 
results the incidence of IBD overall, and UC and CD separately, in western countries is more 
than 2 times higher than the incidence in eastern countries (18.8. vs.7.7 for IBD; 10.1 vs. 4.4 for 
UC and 6.3 vs. 3.1 for CD). Hence, this finding confirms existing east-west gradient of the 
incidence of IBD. Moreover, it also demonstrates an increase in incidence of IBD in eastern 
countries compared to older reports.   




1.2 Etiopathogenesis of IBD 
Although there is a big overlap between CD and UC, the diseases represent two different entities 
characterized also by different leading immunological profile. While CD seems to be mainly T 
helper (Th)1/Th17 cytokine mediated disease in which interleukin (IL)-12, IL-23 and interferon 
(IFN)-γ play a key role; UC is rather Th2 cytokine mediated disease with an IL-5 and IL-13 
being the central cytokines (21). Both diseases then share common cytokines such as tumour 
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necrosis factor (TNF)-α, IL-6 or IL-1βF which are more or less associated with each of the 
disease and are produced mainly by innate immune cells (21;22).  
Despite the long-term intensive research the origin and exact etiopathogenesis of either CD or 
UC is still unknown. Along with the intensive research providing constantly new knowledge, 
several theories have been proposed.   
Mycobacterium avium subspecies paratuberculosis was thought to be an etiologic agent of CD 
(23). This belief arose from a link between a spontaneous granulomatous enterocolitis in cattle 
(Johne´s disease) caused by this microorganism and a later prove of mycobacterium in cultures 
from intestinal specimens, positive serology or molecular biologic techniques. Given the later 
negative studies on mycobacterium detection and lack of efficacy of anti-tuberculosis therapy in 
patients with CD, the proposed theory seems nowadays unlikely for most CD patients (23).   
An increasing incidence of IBD paralleling improvements in hygiene and a higher incidence of 
IBD in developed than in developing countries lead later to a postulation of so called “hygiene 
hypothesis”. The hypothesis was based on an assumption of a decreased microbial exposure in 
childhood resulting in an inappropriate development of immune system and subsequent 
abnormal response to potential pathogenic infectious agent in a later age, leading to development 
of IBD (24).   
Currently, based on new emerging findings in the field of genetics, immunology and 
microbiology research, the most likely and the most accepted theory suggests that IBD results 
from pathological interaction between host immune system and bacterial intestinal flora in an 
individual with a certain genetic predisposition (23).  
 
 1.2.1 Genetics 
Several indications such as increased risk of IBD among relatives, elevated risk of IBD in a 
population of Ashkenazi Jews and mainly twin studies showing higher concordance for IBD in 
mono- compared to dizygotic twins have demonstrated certain impact of genetics on 
pathogenesis of IBD (25-27). The genetic contribution seems to be higher in CD than in UC as 
apparent from twin studies with a higher concordance for CD than for UC (25;26). 
To date, about 100 susceptibility loci have been identified to be significantly associated with 
IBD, encoding products which mediate variety of cell functions (microbial recognition, 
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lymphocyte activation, cytokine signalling and epithelial barrier function) (28). About one third 
of the susceptibility loci are associated with both diseases, the rest are specific either for CD or 
UC (29). Interestingly, there is a big genetic overlap between IBD and other immune and non-
immune disease such ad type 1 and 2 diabetes, celiac disease, psoriasis, ankylosing spondylitis, 
etc (29).  
Although approximately 100 of gene loci associated with IBD have been identified, their 
functional implication in IBD is largely unknown and a lot of loci seem to contribute only 
modestly to IBD risk (28). 
In 2001, an association between polymorphisms in NOD2 (nucleotide binding oligomerization 
domain protein 2) and CD was found, representing a landmark in IBD genetic research (30;31). 
So far, among the identified CD susceptible loci, NOD2 polymorphisms seem to have the 
strongest association with the disease. In European population, individuals carrying at least one 
risk allele of NOD2 were identified to have about 2-fold increase in risk for CD, whereas 
homozygotes or individuals with compound heterozygozity had up to 17-fold increase in risk for 
CD (32). Moreover, NOD2 mutations have been consistently shown to be associated with ileal 
CD localization and stricturing/penetrating disease phenotype (32-34).  
NOD2 is an intracellular receptor for microbial ligands which is broadly expressed in 
macrophages, dendritic cells, Paneth cells and to a lesser amount in intestinal epithelial cells 
(35). NOD2 is activated mainly by N-acetyl muramyl dipeptide (MDP), a bacterial component of 
peptidoglycan which is present in broad classes of bacteria (28;36;37). Stimulation of NOD2 by 
MDP results in activation of transcription factor nuclear factor-B (NF-κB) pathway which is 
involved in expression of immune response genes in the gut (28;35).  
Autophagy and genes encoding proteins involved in autophagy complex have been intensively 
studied during the last years. Autophagy is a process of cell self-degradation of damaged 
organelles and proteins and is important for the clearance of different types of pathogens as a 
part of innate immune system (28;29;38). Several polymorphisms in genes encoding proteins 
responsible for autophagy have been shown to be responsible for inefficient autophagic defence 
response to intracellular intestinal pathogens (38). Impairment in autophagy process is currently 
thought to play an important role in pathogenesis of CD. ATG16L1 (autophagy 16-like 1 
polymorphism) encoding a protein involved in autophagy process, has been identified to be 
strongly associated with CD (39). ATG16L1 is expressed in many cells, including Paneth cells 
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where it mediates exocytosis of secretory granules containing antimicrobial peptides (40). Other 
genes encoding proteins involved in autophagy discovered to be associated with CD are IRGM 
(immunity-related guanosine triphosphatase M) and LRRK2 (leucine-rich repeat kinase 2) 
(41;42). Interestingly, a functional link between NOD2 and ATG16L1 in autophagy regulation 
has been reported (43;44). 
Furthermore, several genes for cytokines and their receptors regulating T-cells have been studied 
in relation to IBD (28;29). Among others polymorphism in IL-23 receptor (IL23R) has been 
identified to be associated with IBD, and also other immune-mediated diseases (28). Molecules 
involved in IL-23 pathway seem to have a crucial role in maintaining intestinal immune 
homeostasis (29). 
Several other genes encoding molecules assumed to be involved in the pathogenesis of IBD have 
been identified. Yet, either their functional role or their significance in the pathogenesis of the 
disease has to be determined.  
 
1.2.2 Microbiota 




 microorganisms consisting of 15,000 to 
36,000 individual species which can be grouped into 4 bacterial divisions: Firmicutes, 
Bacteroides, Proteobacteria and Actinobacteria (23;45). The concentration of microorganisms 









 mainly anaerobic organisms in cecum and colon (23). 
There are several strong indications coming from animal models and human studies that 
intestinal microbiota play a central role in the pathogenesis of IBD. Most of germ-free animal 
models require colonisation with commensal bacteria in order to develop intestinal inflammation 
or immune activation (46;47). Increased levels of mucus- or mucosal-associated and translocated 
bacteria like adherent/invasive E coli strains in ileal mucosa of CD patients, have been found in 
IBD (48;49). In human studies, fecal stream diversion has been shown to either prevent 
recurrence of CD or treat active CD (50). Conversely, early recurrence of CD lesions has been 
observed after infusion of intestinal content to the excluded small bowel (51). There is also some 
evidence of beneficial effect of antibiotics and probiotics in the treatment of IBD (52-54) and a 
proportion of patients with IBD have serologic response towards several bacterial components 
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like ASCA (anti-Saccharomyces cerevisiae antibody), OmpC (antibodies to E coli outer-
membrane porin C) Cbir 1 flagellin (Clostridium species) etc (55). Furthermore genetic 
polymorphisms involved in handling intestinal bacteria like NOD2 mutations or polymorphisms 
in autophagy genes support the theory of bacterial involvement in pathogenesis of IBD.  
 
Dysbiosis  
Intestinal bacterial flora in patients with IBD differs from that of healthy individuals with 
reduced diversity of commensal bacteria and increased numbers of mucosa-associated bacteria 
(48;56;57).  Patients with IBD seem to have reduced number of bacteria with anti-inflammatory 
properties (species of Bacteroides and Firmicutes phyla) and/or increased number of pro-
inflammatory acting microorganisms (Enterobacteriacae; mucolytic bacteria) (48). Furthermore, 
as already mentioned increased levels of mucosa-associated bacteria were found both in CD and 
UC compared to healthy controls (49;57). The clear origin of this dysbiosis in IBD patients is 
unknown and may arise either from host-mediated inflammatory response or from colonisation 
by enteric pathogens, or from combination of these (48). Hence, it is unknown if dysbiosis is a 
primary cause of IBD or just the consequence of the underlying disease (48). 
 
1.2.3 Intestinal defence and immune-tolerance 
In normal healthy individual defensive mechanisms of intestinal epithelial and immune cells are 
in homeostasis with commensal bacteria leading to an immune-tolerance of the gut microbiota. 
However, in patients with IBD several factors of the defense and immune tolerance mechanisms 
seem to be altered leading to disruption of the immune tolerance and inappropriate inflammatory 
response to antigens of autologous flora. 
 
Intestinal defense  
There are several components of defence mechanism including intestinal epithelial cells, innate 
and adaptive immune system and their co-operation, which are so far only partly understood. 
Recognition of intestinal bacteria and subsequent initiation of defense mechanisms is mediated 
via several pattern recognition receptors (PRRs), including toll-like receptors (TLR) and 
intracellular NOD-like receptor family, localized in epithelial and immune-competent cells 
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(22;38;58;59). Intestinal mucosal barrier with epithelial cells and mucus seem to play a central 
role in intestinal immune homeostasis. After activation of expressed PRRs intestinal epithelial 
cells produce cytokines and antimicrobial peptides and regulate intercellular interactions (38). 
Patients with CD, but also their relatives, have been found to have increased intestinal 
permeability, which may promote translocation of bacteria through the intestinal mucosa (60). 
An altered intestinal mucus barrier, particularly in mucus composition, has been demonstrated in 
individuals with UC (61).   
Defensines are small cationic anti-microbial peptides produced mainly by Paneth cells and also 
other intestinal epithelial cells with a broad spectrum activity against bacteria, fungi and viruses 
which represent another part of innate immune defense mechanism of the gut (62-64). An altered 
secretion of these antimicrobial peptides has been described in animal models as well as in 
humans and linked to the polymorphisms in NOD2 receptor (63;64). Thus, it has been 
hypothesized that described association of ileal CD localization with NOD2 mutations might be 
at least partially attributed to an insufficient secretion of defensins, contributing to a breakdown 
of intestinal defence anti-microbial mechanisms (63;64).    
 
Intestinal immune tolerance 
An important feature of properly functioning intestinal immune system is not only efficient 
defence, but also mechanisms ensuring immune tolerance of commensal intestinal microbiota. 
Intact mucus layer and epithelial barrier limit penetration of bacteria into intestinal wall and thus 
minimize the exposure of microorganisms to cells of immune system (38). Furthermore several 
active mechanisms of down-regulation of innate and adaptive immune system exist. These 
include regulation of PRRs expression and responsiveness, secretion of inhibitory mediators and 
modulation of intracellular signalling pathways in distinct immune cells (38). IL-10 is an 
important anti-inflammatory cytokine mediating intestinal homeostasis among others by 
increasing expression of anti-inflammatory cytokines and inhibiting pro-inflammatory ones (28). 
Mice deficient in IL-10 have been shown to develop spontaneous colitis (65), furthermore a 
severe phenotype of CD has been described in patients with loss of IL-10 or its receptor function 
(28;29). Cells of innate immune system, such as lamina propria dendritic cells and macrophages, 
have been in centre of research attention regarding their role in IBD pathogenesis. A certain 
subset of lamina propria dendritic cells and macrophages seem to be important for differentiation 
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and maintenance of regulatory T-cells (Tregs) which are important in control of immune 
response (66;67). Alteration in these innate immune cells has been shown to decrease the number 
of Tregs resulting in an uncontrolled inflammation (38;66).      
To date, far more other pathways of innate and adaptive immune systems have been identified to 
have a conceivable implication in the pathogenesis of IBD. Nevertheless, their functional link 
and mainly their importance in the pathogenesis of the disease have to be yet assessed. It is very 
likely that as IBD seem to be rather a heterogeneous disease; the relative importance of particular 
immune mechanisms may be different in different individuals. This may also be supported by 
differences in responses to particular medical therapies among individuals. 
 
1.2.4 Environmental factors 
Several environmental factors have been proposed to be associated with the risk of development 
of IBD. Some, like smoking have been consistently reported, others like diet are still discussed. 
 
Smoking 
Smoking is a well established factor having impact on development of IBD as well as on 
subsequent course of the disease. Smoking has been identified to be a risk factor for development 
of CD whereas there is an inverse relation with the risk of UC (68;69). Similarly, current 
smoking seems to deteriorate the disease course in patients with CD while its effect on UC is 
opposed (70). Furthermore, a higher prevalence of smokers among CD patients and a lower 
prevalence among UC individuals as compared to the general population have been observed 
(68;70). The exact pathophysiological mechanism of impact of smoking on IBD is unknown and 
proposed to be mediated by its several modulatory effects on humoral and cellular immune 
mechanisms (70).   
 
Antibiotics 
Antibiotics are frequently discussed external risk factor for development of IBD due to their gut 
microbiota modifying potential contributing to dysbiosis. Recently, an interesting Danish 
nationwide cohort study has been published on an association of antibiotic use in paediatrics and 
risk of childhood-onset IBD (71). The authors have found an increased risk for development of 
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CD in antibiotic users with a relative risk of 3.41 (95%CI: 1.45-8.02). The risk of CD was 
greatest in the first 3 months following antibiotic use, for penicillins, in age categories of 3-11 




Appendectomy for appendicitis has been identified as a protective risk factor for development of 
UC (68;72-74). In a Swedish national registry based study patients who underwent 
appendectomy for appendicitis or mesenteric lymphadenitis had a significantly lower incidence 
of UC compared to individuals not having this surgery (incidence-rate ratio 0.73, 95%CI: 0.62-
0.87 and 0.48, 95%CI: 0.27-0.83, respectively) (72). Interestingly, this decreased risk was 
observed only in individuals younger than 20 years of age. Furthermore appendectomies 
performed for nonspecific abdominal pain had no impact on UC development suggesting that 
appendicitis per se is the influencing factor (72). This observation was later supported by a 
nationwide Swedish-Danish cohort study showing that only appendectomies for appendicitis 
reduced the risk of UC onset (74). The etiopathogenetic link between appendicitis and risk of UC 
is unknown and hypothesized to be caused by different immune mechanisms involved in these 
two conditions (72). No or weak association with appendectomy has been observed in case of 
CD (75;76).  
 
Diet  
Several components of diet have been proposed to increase the risk (n-6 polyunsaturated fatty 
acids, animal protein intake, and dietary sugar intake) or to have a protective effect (n-3 
polyunsaturated fatty acids) on development of either CD or UC (68;69). However, overall the 
results seem to be inconsistent, with a risk of methodological recall bias in some studies and 




IBD, as already mentioned, is a chronic lifelong disease characterized by periods of activity and 
remission. The goal of the current medical therapy is to induce remission of active disease and 
thereafter to maintain remission and prevent the relapse occurrence. Medications used for 
induction of remission are characterized by quick onset of anti-inflammatory efficacy and 
include mainly corticosteroids (either systemic or topical), 5-aminosalicylic acid (5-ASA) 
preparations, anti-tumour necrosis factor α (TNF α) monoclonal antibodies and cyclosporine 
(only in UC). Of them 5-ASA preparations and anti-TNFs are indicated also for maintenance 
therapy together with immunosuppressives - thiopurines and methotrexate (only in CD) which 
have a slow onset of their immunosuppressive activity.  In addition to oral or parenteral 
preparations, local forms of corticosteroid and 5-ASA preparations are available in form of 
suppositories, enemas or foams and are prescribed mainly in UC for both active disease and 
maintenance of remission.  
 
1.3.1 Corticosteroids 
The first controlled trial demonstrating the efficacy of glucocorticosteroids in IBD was 
performed in 1955 by Truelove and colleagues using cortisone in patients with active UC (77). 
Subsequent introduction of corticosteroids into clinical practice represented a therapeutic 
landmark in IBD leading to improvement of patients’ prognosis and decrease of previously high 
mortality. Corticosteroids are very potent anti-inflammatory agents with a response rate up to 
90% of treated patients who are naive to this drug (78). Despite the favourable short-term effect 
their use in maintenance therapy is inappropriate due to non-efficacy in this indication and 
mainly because of multiple more or less severe adverse events (79). 
 
Mechanism of action 
The anti-inflammatory effect of glucocorticoids is mediated via binding to a cytoplasmatic 
glucocorticoid receptor which once the ligand is bound to it is moved to nucleus where it directly 
or indirectly regulates the target genes (80). Glucocorticoid –receptor complex binds to a specific 
DNA sequence (glucocorticoid response elements – GRE) which may result either in up-
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regulation of anti-inflammatory genes, such as IL-10, annexin 1 or inhibitor of NF-κB, or 
downregulation of pro-inflammatory genes (81;82). Moreover, glucocorticoids may directly 
interact with NF-κB, activator protein (AP)-1 and other transcription factors and thus inhibit their 
functions (81). The majority of anti-inflammatory effects of glucocorticoids seem to be mediated 
through these inhibitory mechanisms (81). Furthermore, some effects of glucocorticoids are 
believed to be mediated by a distinct membrane receptor linked to a number of intracellular 
signalling pathways (80). Beside interaction of corticosteroids with inflammatory genes, they 
influence also expression of genes involved in metabolic processes resulting in some 
corticosteroid related side effects (81). Hence, novel glucocorticosteroids with strong anti-
inflammatory properties but having considerably reduced risk of side effects have been under 
investigation.  
    
1.3.2 5-aminosalicylic acid 
Sulphasalazine, a combination of 5-ASA azo–bound to the antimicrobial acting sulphonamide - 
sulphapyridine was the first preparation of 5-ASA drugs used in IBD. The azo-bond is split by an 
azo reductase released by colonic bacteria, yielding 5-ASA and sulphapyridine. Later, it has been 
shown that the active therapeutic compound is represented by 5-ASA and sulphapyridine acts 
only as a carrier molecule which is responsible for most of the severe side effects of the drug 
(83-85). Thus in the 2
nd
 half of 1980s new preparations including just 5-ASA (mesalazines) were 
introduced into clinical practice, having the same efficacy as sulphasalazine but considerably 
lower occurrence of adverse events (86-88). 5–ASA in an unprotected form is absorbed already 
in the proximal small intestine, thus precluding the drug to reach the colon in therapeutic 
concentrations (89). So far several formulations have been developed to delay the drug 
absorption classifying 5-ASA preparations into several groups (90;91):   
1. Azo-bonded compounds – carrier molecule is linked to 5-ASA via diazo-bond as in 
sulphasalazine and releases 5-ASA in the colon by bacterial enzymatic activity.  
2. pH-Dependent delayed release mesalazine - preparations are coated with Eudragit, a resin 
designed to dissolve at a certain pH (pH > 6 and 7 for Eudragit-S and Eudraget-L coated 
mesalazine, respectively) and release 5-ASA in the terminal ileum and colon. 
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3. Controlled-release mesalazine – contains microgranules of 5-ASA individually coated 
with semi-permeable ethylcellulose. The drug is steady released along the length of the 
intestine from the upper small bowel to the colon. 
4. pH-Dependent multimatrix mesalazine (MMX) – the delivery system consists of 
hydrophilic and lipophilic matrices enclosed within a gastro-resistant, pH-dependent 
coating which delays release of 5-ASA at pH≥7 (usually in the terminal ileum) and 
enables prolonged exposure of the colonic mucosa to 5-ASA. 
Beside the oral formulations, 5-ASA is available also for rectal application in form of 
suppositories, foams or enemas.  
 
Mechanism of action 
5-ASA preparations, either oral or local, seem to work locally with the effectiveness related to 
the colonic mucosal/epithelial concentrations (92). The exact mechanism underlying its anti-
inflammatory efficacy is not completely known, and seems to be heterogeneous.  
Among the different effector mechanisms of 5-ASA belong modulation of arachidonic acid 
metabolism, modulation of production of inflammatory cytokines and inhibition of activation of 
NFB pathway involved in expression of immune response genes in the gut (93). Furthermore 5-
ASA acts as an antioxidant and free radical scavenger. Nevertheless, the main effect of 5-ASA 
seems to be as peroxisome proliferator –activated receptor –gamma (PPAR-γ) agonist (92;93). 
PPAR- γ is a transcription factor belonging to the nuclear receptor superfamily which mediates 
metabolic and nutritional signals into transcription events. PPAR- γ is expressed in high levels in 
colonic epithelial cells and plays a key role in bacteria-induced inflammation (93;94). The main 
anti-inflammatory effect of 5-ASA is currently thought to be exerted via direct activation of 
PPAR- γ. Furthermore, 5-ASA is believed to have chemoprophylactic effect on colonic neoplasia 




1.3.3 Anti-TNF α  therapy  
Infliximab (IFX) is a chimeric human/murine monoclonal antibody of IgG1 type against tumour 
necrosis factor α (TNFα) cytokine (97). IFX was the first monoclonal antibody shown to be 
effective in treatment of IBD and is used in this indication since 1998 and 2006 in CD and UC, 
respectively (97;98). Due to the chimeric origin of IFX which is probably responsible for 
increased immunogenicity resulting in allergic reactions and probably also contributing to loss of 
response, a fully human anti-TNFα IgG1 antibody –adalimumab- has been later developed (99). 
The drug was introduced into clinical practice for treatment of CD in 2006 and is awaited to be 
soon accepted also for UC (100;101). Both drugs are also affective in treatment of rheumatoid 
arthritis, ankylosing spondylitis and psoriasis (102-107). The 3rd anti-TNFα preparation used in 
IBD is certolizumab which is a PEGylated Fab´ fragment of humanized anti-TNFα monoclonal 
antibody (108). This drug is currently indicated for treatment of active CD and so far available 
only in USA, Switzerland and Russia. Another anti-TNFα preparation is etanercept which is a 
fusion protein consisting of the extracellular domain of TNF receptor and Fc domain of human 
IgG1 antibody (109). Its binding target beside TNFα contains also lymphotoxin α – a property 
not observed in other anti-TNF α preparations. Etanercept has been shown to be very efficacious 
in rheumatologic autoimmune diseases (109;110), however failed to prove its efficacy in 
treatment of IBD (111).  
 
Tumour necrosis factor α 
TNFα is an important proinflammatory mediator of innate and adaptive immunity and seems to 
play a key role in the pathogenesis of IBD and other autoimmune and non-autoimmune diseases 
such as rheumatoid arthritis and psoriasis, congestive heart failure, etc (112). Increased levels of 
this cytokine have been observed in patients suffering from these diseases (113;114). TNFα is 
produced by several cells such as macrophages, T lymphocytes, natural killer cells with the 
monocyto-macrophage population being the largest producers (115;116). The precursor form of 
TNFα is a transmembrane TNFα (mTNFα) expressed on activated macrophages, lymphocytes 
and other cells which is then cleaved by TNFα-converting enzyme to a soluble TNFα molecule 
(116;117). Both soluble and mTNFα have biologic efficacy mediated via type 1 and type 2 TNF 
receptor (TNFR1 and TNFR2) (116). Binding of soluble TNFα to TNFR1 has been thought to 
mediate the most biologic effects of TNFα. However, there seems to be an increasing evidence 
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of an important biologic role of mTNFα and TNFR2. Moreover, mTNFα not only acts as a 
ligand but also serves as a receptor with reverse signalling into cells expressing this molecule. 
This mechanism seems to be involved in the mode of action of anti-TNFα antibodies (116;117).   
The biologic effect of TNFα is pleiotropic, such as cytokine production, cell adhesion molecule 
expression, proliferation and apoptosis, depending on target cell type and amount and rapidity by 
which TNFα  is produced (112;118;119). The exact mechanism by which TNFα may be involved 
in intestinal inflammation is unknown, most likely complex and exerted via several effects on 
immune and non-immune cells and production of molecules involved in immune mechanisms 
(112).     
 
Mechanism of action of anti-TNFα antibodies 
Soon after introduction of anti-TNFs, it has been obvious that blockade of either soluble or 
mTNFα per se cannot explain the pharmacodynamic effect of IFX (112). Since then several 
effector mechanisms of anti-TNFα antibodies have been proposed and so far confirm the 
complexity of mode of action of these drugs and to some extent elucidate the differences in anti-
inflammatory efficacy observed among particular anti-TNFα preparations.  
Complement dependent and antibody dependent cell cytotoxicity of mTNF expressing cells have 
been suggested as a potential mechanism of action of anti-TNFα antibodies (116;120;121). 
However, these findings were later not confirmed when activated normal peripheral blood 
mononuclear cells were used instead of transfected cell lines that may not correspond with the 
behaviour of normal human cells (122).  
Later it has been shown that IFX induces apoptosis in peripheral monocytes from patients with 
steroid refractory CD (123). The apoptotic effect was found to be via binding of the Fab-portion 
of IFX to mTNFα and subsequent activation of the caspase-cascade independent of Fas/FasL 
mediated apoptosis (123). The same effect on peripheral blood monocytes was later 
demonstrated also for adalimumab, but not for etanercept (124). This failure of etanercept was 
speculated to be due to a lower avidity of entanercept to mTNFα, inability of cross-linking 
mTNFα and formation of less stable complexes with mTNFα compared to abovementioned anti-
TNFs (124).  
Another proposed mechanism of action of anti-TNFa antibodies has been via induction of 
apoptosis in activated T cells (125). Lamina propria T cells of patients with CD seem to be 
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resistant to apoptosis which probably plays an important role in controlling of lymphocyte 
proliferation (126;127). IFX has been shown to revert this defective T cell death and to induce 
apoptosis in mucosal and peripheral blood T cells via caspase signalling pathway independent of 
Fas/FasL mechanism (118;128). The proapoptotic effect of IFX has been demonstrated to be 
exerted through binding of IFX to mTNFα expressed in high amounts on activated human T cells 
(118;125).   
A recent study from the Netherlands described an inhibitory effect of IFX and adalimumab on 
proliferation of activated T-cells (129). This effect was mediated via binding of anti-TNFs to 
both mTNFα and Fc receptor on regulatory macrophages. This concept stresses the dependence 
of immunosuppressive effect of anti-TNFs on presence of Fc region on these monoclonal 
antibodies which is responsible for differentiation of blood-derived monocytes to a certain subset 
of regulatory macrophages. Regulatory macrophages then display inhibitory effect on 
proliferation of activated T cells, and produce anti-inflammatory cytokine IL-10 (129). 
Etanercept and certolizumab failed to affect the proliferation of T cells in this study. The reason 
was likely in low binding efficacy to mTNFα of the first preparation and lack of Fc region of the 
later one. In contrast to previous studies, the authors did not prove proapoptotic effect of either 
IFX or adalimumab on T-cells. Their potential explanation was in the use of endogenous levels 
of mTNFα in contrast to overexpression and the use of highly viable peripheral blood 
lymphocytes in previous studies (129). 
Another interesting study on mechanism of IFX action focusing on Tregs in patients with IBD 
was published by a German research group (130). Treg cells, as already mentioned, seem to have 
potent suppressive effect on proliferation of effector T cells and thus to contribute to suppression 
of inappropriate immune response which is thought to be one of the mechanisms leading to IBD 
(131;132). Decreased numbers of Treg cells have been described in active IBD correlating 
inversely with the disease activity (133;134). The authors have shown that apoptosis of Treg 
cells in patients with active IBD is strongly increased and that this may be reversed by IFX 
therapy in individuals responding to anti-TNFα preparation (130). 
  
In conclusion, despite the intensive research in the field of anti-TNFs and emerging new findings 
the exact mechanism of action is largely unknown and still remains somewhat mysterious. It is 
likely that the combination of above mentioned and yet unknown mechanisms play a role in 
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efficacy of anti-TNFα preparations since the described experiments represent mainly in vitro 
single cells systems which may not properly reflect the complexity of the human organism.  
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2 DRUG DEPENDENCY - BACKGROUND 
2.1 Drug dependency 
IBD is a disease of various manifestations regarding disease localization, occurrence of 
complications and frequency of relapses (1). According to this, different behaviour patterns and 
disease courses have been identified classifying patients into several subtypes (6;7;135). Patients, 
however, differ also in response patterns to medications and beside the “classical” response/no 
response, long-term outcome „drug dependency“ has been described in children and adults with 
IBD (78;136-139). The dependent patients represent a specific population of individuals who 
maintain remission while on the treatment, but relapse promptly after drug cessation or dose 
decrease. However, a quick restoration of remission repeating the pattern of former response is 
achieved and sustained when the therapy is re-introduced or dose increased.  
 
2.2 Corticosteroid dependency 
Drug dependency in IBD was for the first time described in corticosteroid treatment in 1994 in a 
population based study of newly diagnosed patients with CD from Copenhagen County (78). In 
an inception cohort of 109 CD patients naive to corticosteroids, 36% became steroid dependent 
after the 1
st
 treatment course. Corticosteroid dependency was defined as relapse within 30 days 
after steroid discontinuation, or at dose decrease impeding discontinuation of steroids for more 
than 1 year (78). 
Since then, frequency of corticosteroid dependency has been studied in several population-based 
and referral centre studies using modifications of the primary definition (137;138;140-143).  
In 2006 the definition of corticosteroid dependency was implemented into European Crohn´s and 
Colitis Organisation (ECCO) guidelines for CD, later for UC in 2008 and also accepted by the 
Food and Drug Administration (FDA) agency as one of the end points for randomized controlled 
trials (144;145). 
Population-based studies demonstrated that 28-36% of adult CD patients and 22% of UC patients 
became steroid dependent (78;137). Among paediatrics, 24-39% of CD children and 14-50% of 
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UC children were found to develop corticosteroid dependency (138;143;146;147). Similar results 
were found in studies of selected cohorts (140;142;148-150). 
 
2.3 Infliximab dependency 
Biological treatment, including infliximab (IFX), is nowadays considered the most potent anti-
inflammatory therapy in IBD indicated in approximately 20-30% of patients who have severe 
and complicated disease course (79;88). The efficacy of IFX has been proven in both CD and 
UC, in adult as well in paediatric population, for induction and also maintenance therapy 
(97;98;151-154).  
Soon, after introduction of IFX in to clinical practice, it was recognized that similarly to 
corticosteroid therapy, some patients were able to discontinue IFX and maintain long-term 
remission without further need of infusions, whereas a significant proportion of them relapsed 
shortly after drug withdrawal and required IFX re-introduction to sustain the remission. This 
response pattern was first described in 2006 in a retrospective paediatric study from Denmark 
and defined as IFX dependency (139). Children were considered IFX dependent if they relapsed 
within 90 days after IFX discontinuation but regained remission after its re-introduction. Of the 
24 patients included 42% were found to be IFX dependent (139). Later, a national cohort of CD 
children from the Netherlands has been assessed for IFX dependency (136). Of 66 treated 
children, 56% were classified as IFX dependent (136).  
So far, the use of IFX seems to be safe (152;155;156), nevertheless potential side effects such as 





consequences of the long-standing therapy are still being monitored. Moreover, the treatment is 
relatively expensive and the cost effectiveness is essential (162;163). Seen from these 
perspectives, early identification of prolonged responders and IFX dependent patients might be 
helpful in clinical practice when deciding for long-term treatment. 
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2.4 5-ASA dependency 
5-ASA preparations are broadly used in mild to moderate UC showing efficacy in induction as 
well as in maintenance of remission (164;165). Contrary to this, the role of 5-ASA in CD is 
controversial. Several trials comparing effect of 5-ASA to placebo in CD patients have been 
done with divergent results (166-171). A meta-analysis investigating efficacy of 5-ASA in 
treatment of active CD and 2 meta-analyses focused on maintenance therapy failed to prove its 
efficacy (172-174). Consequently, the use of 5-ASA in CD was not more recommended (175). 
Nevertheless, the studies included were differently designed, the study population was quite 
heterogeneous and different drug formulations and dosages were used. Moreover, there is 
evidence from population based studies that a significant proportion of CD patients has a mild 
disease course (6;176). Furthermore, the newer 5-ASA preparations have a very good safety 
profile comparable to placebo (86).  
The role of 5-ASA in CD is therefore still unclear and several factors indicate that there is a 
subgroup of CD patients who may benefit from 5-ASA therapy. Such individuals can be 
observed in clinical practice showing the similar dependent response pattern as seen in 
corticosteroid or IFX treatment.   
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 3     HYPOTHESES 
3.1   Paper I & II 
The hypotheses of our study were: 
1. IFX dependency occurs in approximately 50% of treated patients with an equal frequency 
in adult and paediatric patients 
2. Clinical or genetic predictors of IFX dependency might better identify these patients who 
are in need of long-term IFX treatment 
3. Contrary to corticosteroids, IFX dependency is associated with a favorable long-term 
prognosis having a low risk of surgery 
 
3.2    Paper III 
The hypotheses of our study were: 
1. 5-ASA is efficacious therapy in a certain population of CD patients 
2. Similar dependent pattern as in steroids or IFX is observed also in 5-ASA therapy 
3. Predictors of long-term outcome of 5-ASA treatment may help to better select the 













4.1 Paper I & II 
The aims of our study were to: 
1. Assess the frequency of IFX dependency in paediatric (Paper I) and adult (Paper II) patients 
with CD 
2. Search for clinical and genetic predictors of IFX outcome  
3. Evaluate the impact of IFX dependency on the surgical rate  
 
4.2 Paper III 
The aims of our study were to: 
1. Assess the outcome of the first course of 5-ASA monotherapy with emphasis on 5-ASA 
dependency in patients with CD  







5 MATERIAL & METHODS 
5.1 Paper I & II 
5.1.1 Study population 
Paediatric cohort 
The study population included consecutive pediatric patients with CD treated with IFX who 
originated from: a) Danish Crohn Colitis Database (DCCD) treated at two departments of 
pediatrics in Denmark (Hvidovre and Odense University Hospital) from August 2000 until 
November 2006; b) the Czech Republic treated with IFX at two departments of pediatrics in 
Prague (Hospitals of the 1st and the 2nd Faculty of Medicine, Charles University) from October 
2002 to June 2006. The diagnosis of CD of all patients was assessed according to the 
international diagnostic criteria (177).  
Adult cohort 
The study population comprised consecutive CD patients from the DCCD treated with IFX at 
Herlev and Slagelse University Hospitals between June 1999 and July 2006 and from the Czech 
Republic treated at Charles University Hospital in Prague between January 1999 and December 
2005. The diagnosis of CD of all patients was assessed according to the international diagnostic 
criteria (144).  
Controls 
Healthy individuals, 182 from Denmark and 283 from the Czech Republic, were included as 
controls in the genotype-phenotype association study. 
 
5.1.2 Infliximab therapy 
IFX therapy was indicated for luminal disease (refractory or intolerant to conventional treatment, 
corticosteroid dependency) and perianal disease. The treatment strategy and cessation of the 
therapy were individualized with respect to patients’ clinical condition and decision of treating 
physician. According to schedule of IFX administration, the treatment strategy was 
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 week); (2) 
induction therapy followed by scheduled maintenance therapy every 6 or 8 weeks and (3) on 
demand therapy when after the initial 1 to 3 infusions, the following infusions were given as 
non-scheduled in accordance to patient´s disease activity.  
 
5.1.3 Data collection 
Data on demographics and disease characteristics at IFX start including gender, age, disease 
localization and behaviour, disease duration, history of previous surgery; details on IFX therapy, 
concomitant medication and surgical treatment were retrieved from medical records.   
 
5.1.4 Assessment of IFX outcome  
Clinical outcome of IFX therapy was retrospectively assessed according to a modified phenotype 
model of IFX dependency developed and described previously
 
(Table 1).  
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Table 1. Phenotype model of IFX dependency 
Immediate outcome 
    30 days after the first infusion 
Long-term outcome 
3 months after last intended infusion 
Complete response 
-Luminal disease: Total regression of symptoms: ≤2 
stools/day (after surgery +2 stools). No blood, pus, 
mucus, abdominal pain and weight loss. 
-Perianal disease: Closure of all fistulas evaluated by 
thumb pressure or patients announcement of “no 
secretion”. 
Prolonged response 
Maintenance of complete or partial response. 
 
Partial response 
-Luminal disease: Regression of symptoms: ≤4 
stools/day (after surgery +2 stools); blood, pus, 
mucus, abdominal pain less than daily, no fever and 
weight loss.  
-Perianal disease: Reduced secretion or discomfort 
from fistulas or closure of one or some of the fistulas. 
IFX dependency 
Relapse requiring repeated infusions to regain the 
complete or partial response; patients who needed 
IFX therapy for more than 12 months to sustain 
response were also considered IFX dependent. 
 
No response 
-Luminal/perianal disease: No regression of 
symptoms with a need to shift to another 
immunomodulator and/or surgery within 3months 
after initiation of IFX. 
No response 
No improvement or worsening of symptoms with a 
need to shift from IFX treatment to another 










The last intended infusion meant the primary decision of treating clinician to stop IFX therapy. 
Since the number of infusions given prior to intended IFX stop differed among the patients the 
long-term outcome was evaluated irrespective of the prior treatment length.  
Immunomodulator was defined as corticosteroids, thiopurines, methotrexate and other biological 
drugs.  
Surgery was classified as intestinal (resection, strictureplasty, colectomy) or perianal (incision of 
abscess, fistulotomy, advancement flap). Incision of perianal abscess as a possible consequence 
of healing process during IFX treatment was not considered as surgery.  





 etc. course. Only the 1
st
 treatment course was analyzed in this study. 
 
5.1.5 Genetic polymorphisms 
Following candidate variants were selected as conceivable predictors of IFX outcome:  TNF c.-
1037 C>T, TNF c.-488 A>G, CASP9 c.93 C>T, LTA c.207 A>G and FASLG c.-844 C>T.  
Genomic DNA was isolated from peripheral blood by routine salting out procedure (Czech 
Republic) or from buccal swab (Denmark) using Qiagen DNA purification Kit (Qiagen, Hilden, 
Germany). All polymorphisms were typed using PCR- restriction fragment length polymorphism 
as described in Paper I.  
To ensure consistency between runs, samples of known genotypes were repeated in every 
analysis. DNA samples were analysed under numeric codes, and genotype-phenotype matching 
was done at the end of the study. Genotypes of controls were in Hardy-Weinberg equilibrium. 
Czech and Danish cohorts were analyzed separately due to significant differences of TNF c.-
1037 C>T, TNF c.-488 A>G, LTA c.207 A>G and FASLG c.-844 C>T variants in general 
populations.  
 
5.1.6 Statistical analysis 
Empirical transition probabilities from immediate outcome to long-term outcome were 
calculated. Univariate logistic analyses were carried out analyzing the probability of being 
prolonged responder and/or IFX dependent at long-term outcome. Fisher exact test was used 
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when appropriate. Chi-square test and Fisher exact test were used to compare allelic and 
genotype frequencies and to analyze an association of present variants with response to IFX. 
Patients´ clinical and demographic characteristics were compared by Mann-Whitney test or Chi-
square test. Kaplan-Meier curves with accompanying log-rank test were done for time until 
surgery. A significance level of 5% was chosen.  
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5.2 Paper III 
5.2.1 Study population 
The study population consisted of CD patients from DCCD treated at Herlev University Hospital 
in a time period from 1953 to 2007. From May 2007 to April 2008 the medical records of all CD 
patients were scrutinized to abstract information on treatment with per oral and topical 5-ASA 
preparations. Patients fulfilling the following inclusion criterion were included into data 
analyses: „Relapse of the disease with the intention to treat only with 5-ASA preparations during 
the disease course“.  
 
5.2.2 Data collection 
Data on age, gender, disease duration, previous surgery, disease behaviour and localization at the 
start of 5-ASA monotherapy and the details on 5-ASA treatment were retrieved from medical 
files.  
 
5.2.3 Assessment of 5-ASA response 
Response to 5-ASA treatment was evaluated retrospectively according to a developed phenotype 
model of 5-ASA dependency (Figure 2).  
 
Immediate outcome: 30 days after the start of 5-ASA therapy 
1. Complete response: Total regression of clinical symptoms 
2. Partial response: Improvement of clinical symptoms  
3. No response: No regression of symptoms with a need to shift from 5-ASA to 
immunomodulator and/or surgery  
 
Long-term outcome: irrespective of the length of the treatment 
1. Prolonged response: Still in complete/partial response one year after induction of 
response, either on the initial/reduced dose of 5-ASA or after 5-ASA discontinuance 
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2. 5-ASA dependency: Relapse within one year after 5-ASA treatment cessation and regain 
of complete/partial response after 5-ASA re-introduction or relapse on a dose reduction 
or stable dose requiring dose escalation to regain complete/partial response 
3.  No response: No regression of symptoms with a need to shift from 5-ASA treatment to 
immunomodulator therapy and/or surgery 
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Immunomodulator therapy included corticosteroids (intravenous, per oral, enemas/foams), 
thiopurines, methotrexate and biological drugs. Surgery was defined as intestinal (resection, 
strictureplasty, colectomy) or perianal (incision of abscess, seton, fistulotomy).  
A new relapse with the intention to treat only with 5-ASA >1 year after the previous 5-ASA 
course or after the immunomodulator treatment or surgery was considered as the 2nd, 3rd etc. 
course. Only the 1st treatment course was analyzed. 
 
5.2.4 Statistical analysis 
Logistic regression analyses were performed in order to investigate which disease characteristics 
were predictable for a certain treatment response. Kaplan-Meier curve with accompanying log-
rank test was done for cumulative probability of surgery. A significance level of 5% was chosen. 
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6 RESULTS 
6.1 Paper I 
A total of 82 children with CD were included, 41 from Denmark and 41 from the Czech 
Republic. Baseline demographic and clinical characteristics are outlined in Table 2. The median 
(range) follow-up after start of IFX therapy was 45 (3-75) and 21 (6-50) months for Danish and 
Czech children, respectively. 
 
Table  2. Patients´ demographic and clinical characteristics at start of IFX therapy 
 Danish (n=41) Czech (n=41) p 
Median age (range)                14 (9-18) 15 (8-18) 0.58 
Female (%) 23 (56%) 19 (46%) 0.38 
Median disease duration (yr) 2 (0-7) 2 (0-6) 0.50 
Disease localization (%)  
    Ileum (L1) 
    Colon (L2) 
    Ileo-colon (L3) 





9   (22) 
 
3   (7) 
10 (24) 
20 (49) 






Disease behaviour (%) 
    Inflammatory (B1) 
    Stricturing+penetrating (B2+3) 
    Perianal+ B1/2+3 
 
24 (58) 







Prior intestinal surgery (%)      8 (20) 3 (7) 0.19 
Concomitant immunosuppressive therapy  
(thiopurines /methotrexate) (%)   
36 (88) 
 




IFX was indicated for luminal and perianal disease in 62 and 20 children, respectively. Twelve 
children received only induction infusions, 38 children were treated with induction infusions 
followed by maintenance therapy (median: 10 infusions; range: 5-21) and 31 received IFX on 
demand (median: 6; range: 1-27) (Table 3). In 2 patients on maintenance therapy, the dose of 
IFX was increased to 10 mg/kg later in the treatment course due to loss of efficacy. One patient 
was lost from the follow-up.  
 
Table 3. Details on IFX therapy in paediatric patients with CD with respect to country of origin 
  Danish (n=41) Czech (n=41) p 
Indication to IFX - Luminal disease 
- Perianal disease  
35 (85) 






- Only induction 
- Maintenance 
- On demand 
6   (15) 
14 (34) 
21 (51) 






6.1.1 Outcome of infliximab treatment 
The immediate response was obtained in 77 (94%) children of whom 65 (79%) obtained 
complete and 12 (15%) partial response. In long-term outcome 18 (22%) patients achieved 
prolonged response, 53 (66%) developed IFX dependency and 10 (12%) patients were non-
responders. The median number of infusions given were 3 (range: 1-6) to prolonged responders, 
10 (5-27) to IFX dependent children and 2 (2-3) to non-responders. 
Transition probabilities from immediate to long-term outcome are shown in Figure 3. 
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6.1.2 Clinical predictors 
Inflammatory disease behavior (OR ∞, 95%CI: 3.23-∞) was predicative of prolonged response 
or IFX dependency while prior intestinal surgery decreased the probability of this response (OR 
0.05, 95%CI: 0.01-0.32). 
Regarding IFX dependency, complete immediate response (OR 3.9, 95%CI: 1.13-13.22), 
perianal disease (OR 5.34, 95%CI: 1.24-22.55) and no prior intestinal surgery (OR 6.7, 95%CI: 
1.67-26.61) were associated with IFX dependent response (Table 4).  
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Table 4. Clinical predictors of long-term outcome in children with immediate complete or partial 
response to IFX (n=76) 
 
 
Prolonged response & 
IFX dependency 
IFX dependency 
Predictor variable OR (95%CI) OR (95%CI) 
Czech vs. Danish 2.24 (0.37-13.53) 1.08 (0.40 - 2.90) 
Male gender 1.00 (0.18-5.48) 1.28 (0.47-3.43) 
Age at IFX start 












 -Colonic vs.  Ileal 
 -Ileocolonic vs. Ileal 








1.09 (0.15- 8.12) 
Behaviour 
- Non-inflammatory vs. Inflammatory  
 
0 (0 – 0.31)* 
 
0.39 (0.11-1.32)  
Prior intestinal surgery  0.05 (0.01 - 0.32)* 0.15 (0.03-0.66)* 
Indication to IFX 




0.19 (0.04- 0.92)* 
Concomitant immunosuppressants 3.30 (0.29 - 37.11) 1.48 (0.22- 9.89) 
Immediate outcome 
-Partial vs. Complete  
 
0.33 (0.05 - 2.14) 
 
0.26 (0.07 - 0.95)* 
OR, odds ratio; CI, confidence interval; * statistically significant results 
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6.1.3 Genetic predictors  
No association was found between studied polymorphisms and IFX outcome (Table 5). 
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Table 5. Minor allele frequency (%) vs. IFX outcome in children with CD  











Variant  CR+PR     NR  
 (n=15)    (n=1) 
PRO+ID    NR  
 (n=14)    (n=1) 
ID    PRO+ NR 
(n=11)   (n=4) 
 CR+PR     NR  
(n=35)      (n=1) 
PRO     ID     NR 
(n=9)  (n=25)      (n=0) 
FASLG c.-844 C>T                           37         50   56             50    32             50   41              100  22           48         - 
CASP9 c.93 C>T                       17  50  18               0  18            12.5   26               50  28           26          - 
LTA c.207 A>G                             30 50  32               0    32             25   36               50  28           38          - 
TNF c.-488 A>G                         13         50  17               0    18              0   13               50  11           14          - 
TNF c.-1037 C>T                     0    0    0               0      0              0   11                0  11           12          - 
CR, complete response; PR, partial response; NR, no response; PRO, prolonged response; ID, IFX dependency
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6.1.4 Surgery 
The cumulative probability of surgery is outlined in Figure 4. Fifty months after the start of IFX 
therapy the risk of intestinal surgery was 10% in IFX dependent patients, 30% in prolonged 
responders and 70% in non-responders (p=0.0002). IFX dependent children had significantly 
lower surgery rate compared to those with prolonged response (p=0.036). 
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Figure 4. Proportion of CD patients without intestinal surgery after the start of IFX therapy  
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6.2 Paper II 
The study cohort comprised 132 CD patients from Denmark and 113 from the Czech Republic 
with the median (range) follow-up of 37.5 (6-92) and 38 (13-89) months respectively. The 
baseline demographic and clinical characteristics are presented in Table 6.  
 
Table 6. Patients´ demographic and clinical characteristics at start of IFX therapy 
 Danish (n=132) Czech (n=113) p 
Medina age (range)                34 (15-66) 31 (16-67) 0.08 
Female (%) 72 (58%) 60 (53%) 0.48 
Median disease duration in years (range) 6 (0-33) 5 (0-39) 0.50 
Disease localization (%)  
    Ileum (L1) 
    Colon (L2) 
    Ileo-colon (L3) 
















Disease behaviour (%) 
    Inflammatory (B1) 
    Stricturing+penetrating (B2+3) 










Prior intestinal surgery (%)      56 (42) 64 (57) 0.03 
Concomitant immunosuppressive therapy  
(thiopurines/methotrexate) (%)   
114 (86) 
 
79 (70) 0.002 
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The indication for IFX therapy was luminal and perianal disease in 132 and 114 patients, 
respectively. Induction therapy only was given to 47% of patients, induction followed by 
maintenance therapy to 14% of patients (median 8 infusions, range: 4-17) and on demand 
therapy to 39% of patients (median 4 infusions, range: 1-28) (Table 7). The interval between 
infusions given on demand was 6-50 weeks. Two patients needed to increase the dose of IFX to 
10 mg/kg during the treatment course.  
 
Table 7. Details on IFX therapy in patients with CD with respect to country of origin 
  Danish (n=132) Czech (n=113) p 
Indication to IFX  - Luminal disease 








- Only induction 
- Maintenance 









6.2.1 Outcome of IFX treatment 
Immediate response was observed in 210 (86%) patients: 136 (56 %) patients achieved complete, 
74 (30%) partial and 35 (14 %) had no response. 
In long-term outcome 114 (47%) patients obtained prolonged response, 71 (29%) developed IFX 
dependency and 60 (24%) had no response. The median number of infusions was 3 (range: 1-7) 
in prolonged responders, 9 (3-28) in IFX dependent patients and 3 (1-7) in non-responders.  
The analysis of transition probabilities from immediate to long-term outcome with respect to 
immediate response is outlined in Figure 5. 
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Figure 5. Transition probabilities from immediate to long term-outcome 
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6.2.2 Clinical predictors  
Patients with an immediate complete response were more likely to sustain prolonged response or 
develop IFX dependency than those with partial response (OR 2.65; 95%CI: 1.54 – 6.09). Prior 
intestinal surgery was shown to be negatively associated with IFX dependent phenotype (OR 
0.45; 95%CI: 0.24-0.82). Czech patients developed significantly less IFX dependent response 
than Danish patients (OR 0.37; 95%CI: 0.20-0.69) (Table 8).  
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Table 8. Clinical predictors of long-term outcome in CD patients with immediate complete or 
partial response to IFX (n=210) 
 Prolonged response & 
IFX dependency 
IFX dependency 
Predictor factor OR (95%CI) OR (95%CI) 
Czech vs. Danish 0.78 (0.33 – 1.84) 0.37 (0.20 – 0.70)* 
Male gender 1.19 (0.50 – 2.85) 0.76 (0.42-1.38) 
Age at IFX start 
  >40 yr vs. ≤40 yr 
 




 >2 yr vs. ≤2 yr 
 




 -Colonic vs.  Ileal 
 -Ileocolonic vs. Ileal 








3.15 (0.85- 11.61) 
Behaviour 




0.57 (0.23-1.44)  
Prior intestinal surgery  0.54 (0.23-1.29) 0.45 (0.24-0.82)* 
Indication to IFX 




1.51 (0.84- 2.73) 
Concomitant immunosuppressants 1.26 (0.46 - 3.45) 1.41 (0.66- 3.00) 
Immediate outcome 




1.10 (0.60 – 2.01) 
OR, odds ratio; CI, confidence interval; * statistically significant results 
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6.2.3 Genetic predictors 
Two variants were found to be associated with IFX outcome. Danish patients carrying at least 
one G allele of LTA c.207 A>G variant were more likely to become prolonged responders or IFX 
dependent compared to those homozygous for A allele (93% vs. 69%, respectively; OR 6.04, 
95%CI: 1.48-25.26). In Czech patients, IFX dependent phenotype was associated with the 
presence of at least one T allele of CASP9 c.93 C>T variant (CT/TT vs. CC: 37% vs. 14%, OR 
3.55, 95%CI: 1.21-10.37) (Table 9).  
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Table 9. Genotype frequencies vs. IFX outcome in patients with CD 
 
  Denmark Czech Republic 
Variant Genotype Immediate outcome 
(n=100) 
 
CR+PR        NR 




PRO+ID        NR            ID 




CR+PR       NR 




PRO+ID          NR             ID 
   (n=58)          (n=10)       (n=19) 
FASLG c.-844 C>T 




29              7 
39              4 
18              3 
26                3               9 
34                5             20 
17                1             10 
35            8 
35            5 
 7            0 
      28                  7               6 
32                  3              10 
7                  0                3 
CASP9 c.93 C>T 




53              6 
27              7 
6              1 
45                8             20 
26                1             15 
6                0               4 
42           7 
28           6 
7            0 
  36                  6                6 * 
24                  4              11 
7                  0                2 
LTA  c.207 A>G        




13              3 
36              5 
37              6 
9*              4               7 
33                3             16 
35                2             16 
 5            2 
33            6 
39            5 
 4                  1                1 
30                  3                6 
33                  6              12 
TNF  c.-488 A>G 




3              0 
26              5 
57              9 
2                1               1 
23                3             14 
52                5             24 
 2            0 
15            2 
60          11 
 2                  0                0 
13                  2                3 
52                  8              16 
TNF c.-1037 C>T 




72            10 
14              4 
0              0 
63                9             32 
14                0               7 
  0                0                0 
57          13 
19            0 
1            0 
50                  7              14 
16                  3                5 
 1                  0                0 
*statistically significant result  
CR, complete response; PR, partial response; NR, no response; PRO, prolonged response; ID, IFX dependency
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6.2.4 Surgery  
The cumulative rate of intestinal surgery 40 months after the start of IFX was 20% in prolonged 
responders, 23% in IFX dependent patients and 76% in non-responders (p<0.001) (Figure 6). 
Danish patients had significantly higher risk of surgery than the Czech patients (p=0.04) (Figure 
7). 
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Figure 6. Proportion of CD patients without intestinal surgery after the start of IFX therapy 
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Figure 7. Cumulative probability of surgery after IFX start with respect to country of origin  
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6.3 Paper III 
Five hundred thirty-seven patients with CD from DCCD were identified to be treated at Herlev 
University Hospital. In 7 patients medical records were not available and 185 were either never 
treated with 5-ASA or the information about previous 5-ASA treatment was missing due to 
incomplete medical records. Of the rest 345 patients treated with 5-ASA, 165 fulfilled the 
inclusion criterion and were assessed according to phenotype model of 5-ASA dependency. The 
median (range) follow-up since 5-ASA monotherapy start was 137 months (6-670). Proportion 
of included patients per decade of diagnosis is shown in Table 10 and the clinical and 
demographic characteristics at start of 5-ASA monotherapy are outlined in Table 11. 
 
Table 10. Proportion of CD patients on 5-ASA monotherapy with respect to decade of diagnosis 
Decade of diagnosis  n=165 
   1953 – 1969 
   1970 – 1979 
   1980 – 1989 
   1990 – 1999 








Table 11. Demographic and clinical characteristics of CD patients at start of 5-ASA 
monotherapy 
 n=165 
Male (%) 71 (43) 
Age (yr): median (range)           33 (13-83) 
Disease duration (yr): median (range)       0 (0-49) 
Disease localization (%) 
    Terminal ileum 
    Colon 
    Ileo-colon 
    Upper disease +/- ileum and/or colon 





8   (5) 
4   (2) 
Disease behaviour (%) 
    Inflammatory 
    Stricturing  
    Penetrating 






Perianal disease at any time prior to 5-ASA monotherapy (%) 21  (13) 




6.3.1 5-ASA treatment outcome 
The immediate and long-term outcome of the 1
st
 course of 5-ASA monotherapy is presented in 
Figure 8. The median duration of 5-ASA course was 34 months (range: 1-304) in patients with 
prolonged response, 63 (6-336) in 5-ASA dependent patients and 2 (0-10) in non-responders. 
The daily dose of 5-ASA ranged from 1 to 4.8g. 
Five (3%) patients were not assessed in long-term outcome due to a short treatment course. 
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Figure 8. The outcome of the 1
st
 treatment course with 5-ASA in patients with CD 
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Kaplan-Meier analysis illustrates the cumulative probability of the first intestinal surgery since 
the diagnosis with respect to long-term outcome (Figure 9). 5-ASA dependent patients had 
significantly lower surgical risk than non-responders (p=0.007); no significant difference was 
observed between prolonged responders and non-responders (p=0.1).  
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Figure 9. Proportion of CD patients without intestinal surgery since diagnosis with respect to 
long-term outcome of 5-ASA monotherapy 
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6.3.2 Predictors of 5-ASA response 
Logistic regression analyses identified female gender as predictor of favourable long-term 
outcome - prolonged response or 5-ASA dependency (OR 2.89, 95%CI: 1.08-7.75).  
Focusing on 5-ASA dependent response, patients with longer disease duration were more likely 
to become 5-ASA dependent (OR 4.06, 95%CI: 1.09-15.1) (Table 12).  
 
Table 12. Clinical predictors of long-term outcome of 5-ASA monotherapy in CD patients with 
immediate complete or partial response (n=119) 
 Prolonged response & 
5-ASA dependency 
5-ASA dependency 
Predictor factor OR (95%CI) OR (95%CI) 
Male gender 0.33 (0.12 –0.92)* 1.19 (0.42-7. 3.34) 
Age at IFX start 
  >40 yr vs. ≤40 yr 
 




 >3 yr vs. ≤3 yr 
 




 - Colonic/ileocolonic vs. Ileal  












0.53 (0.05-5.93)  
Prior intestinal surgery  0.58 (0.13-2.62) 0.54 (0.11-2.65) 
OR, odds ratio; CI, confidence interval; *statistically significant results 
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7 DISCUSSION 
IBD is a complex immunopathological disorder of unknown aetiology involving several 
inflammatory mechanisms of different importance in inflammatory process. Based on various 
clinical presentations the disease seems to be rather a group of heterogeneous entities having 
probably more or less different pathophysiological background. This heterogeneity may be seen 
also in wide inter-individual variability in drug response resulting in several drug response 
phenotypes. Whereas some patients respond completely, others experience only improvement of 
the symptoms and a proportion of individuals have no response at all. In the long-term 
perspective, loss of initially good response occurs in some patients while the others develop 
dependency to the drug and can´t be weaned off the drug due to a prompt relapse of the disease 
after its cessation or dose decrease. The pathophysiological mechanisms responsible for these 
response phenotypes are being studied and so far are only partially understood.      
    
Ten to 35% of IBD patients do not respond to anti-TNFα therapy being primary non-responders 
(100;155;178-180). Although TNFα seems to play a central role in inflammatory process in 
majority of individuals, several different, probably TNFα independent inflammatory pathways 
involved in inflammation of IBD have been identified (116). It is likely that these alternative 
inflammatory mechanisms dominate in patients with primary non-response and TNFα plays only 
minor or no role at all. 
Eleven to 50% of patients lose their response during the treatment course being secondary anti-
TNFα failures (181;182). Hypothetically, two different situations may be responsible for loss of 
response to anti-TNFα therapy: 1) pharmacokinetic mechanisms leading to low serum drug 
levels; b) loss of dominancy of pharmacodynamic effect of these preparations in inflammatory 
process.  
Low serum trough levels of both IFX and adalimumab have been associated with worse 
treatment outcome in term of clinical response, endoscopic healing, length of sustained response 
and surgery rate as compared to therapeutic drug levels (183-186). Several mechanisms resulting 
in an increased clearance of the drug may be involved:  
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Anti-TNFs are protein molecules with immunogenic potential leading to anti-drug antibodies 
formation. IFX, due to its chimeric molecular structure is more immunogenic than fully human 
adalimumab with a reported frequency of anti-drug antibodies of 0.9-61% and 0.04-17% for IFX 
and adalimumab, respectively (100;184-191). Formation of anti-drug antibodies has been 
thought to be an important mechanism responsible for increased clearance of the drug and 
subsequent its low serum concentrations.  Nevertheless, a substantial proportion of patients have 
low serum drug levels with negative antibodies suggesting also other mechanism to be involved. 
Higher consumption of IFX due to high TNFα “load” has been suggested as another factor 
contributing to low serum IFX levels (102). In a study of rheumatoid arthritis patients published 
by Bendtzen et al., individuals with higher pre-treatment disease activity had lower initial IFX 
levels than “less sick” patients, with this difference disappearing later in the treatment course 
(102). The authors hypothesized that higher TNFα burden in sicker patients might have lead to 
higher IFX clearance and subsequent lower drug levels (102). 
Finally, anti-TNFα antibodies are proteins which to some extent share metabolic pathways with 
serum immunoglobulins and other proteins. Active inflammation is associated with enhanced 
protein catabolism and increased production of pro-inflammatory molecules instead; furthermore 
there is an increased loss of proteins via inflamed mucosa. A good correlation between IFX 
levels and serum albumin has been shown (192;193). Serum albumin and IgG immunoglobulins 
share common receptor (neonatal Fc receptor – FcRn) which is involved in their homeostasis and 
protects albumin and IgGs from the catabolism (192). Hence, serum albumin level has been 
proposed as an indicator of a degree of catabolism of immunoglobulines including IFX 
antibodies (192;193).     
The impact of the drug levels on anti-TNFα efficacy may be well illustrated by possibility to 
regain the response in some anti-TNFs failures using treatment intensification. The principle of 
this approach is via increasing the dose and/or shortening the interval between drug applications 
to increase the serum level of the drug. So far, intensification seems to work best in individuals 
with a low or no levels of the drug (194-196).  
Nevertheless, it has to be emphasized that although patients with therapeutic drug levels seem to 
have better overall treatment outcome, the pharmacokinetic parameters of anti-TNFs do not have 
to relate necessarily to clinical response. Fourteen to 27% of patients on IFX have good long-
term response despite subtherapeutic or undetectable IFX levels (185;186). On the other hand a 
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proportion of patients lose their response despite high serum levels of the drug (194). This 
corroborates the complexity of mechanism of action of these preparations.   
As mentioned above several other TNFα independent inflammatory pathways have been 
identified to mediate inflammation in IBD as well (116).  One can hypothesize that a shift of a 
dominant mechanism of inflammation from preferentially TNFα dependent to mainly TNFα 
independent may be responsible for loss of pharmacodynamic effect of anti-TNFs and 
subsequent loss of response (116). This situation might play the central role in individuals who 
become anti-TNFα failures despite high levels of the drug in serum.  
Moreover, anti-TNFα therapy per se might have a potential to induce or up-regulate other pro-
inflammatory pathways which may also contribute to secondary anti-TNFα failure (116).   
Another consequence of activation of non-TNFα inflammatory mechanisms is development of so 
called “paradoxical inflammatory events” in individuals with immune mediated inflammatory 
disorders such as IBD or rheumatologic diseases. There is an increasing evidence of de novo 
occurrence of rheumatologic problems, psoriasis or psoriasis-like skin disorders in patients with 
IBD while on anti-TNFs (197-199). Similarly, new onset of IBD has been reported in 
rheumatologic patients treated with these monoclonal antibodies (200).  
 
Recently a new response phenotype to IFX therapy, IFX dependency, has been described 
(136;139). IFX dependent patients are very good responders who, however relaps quickly once 
the drug is stopped or dose decreased.  This is in contrast to patients with prolonged response 
who also respond well to the drug, but maintain the remission even after drug cessation. So far, 
no pathophysiological concept for IFX dependency has been proposed. Hypothetically, this 
difference in their ability to sustain the remission upon drug stop might be given by the 
difference in durability of the pharmacodynamic effect. While it might lead to a long-term down-
regulation of the inflammatory process in prolonged responders it results only in a time limited 
effect in dependent individuals. Nevertheless, the inflammation seems to be mediated all over by 
the same inflammatory mechanisms since dependent patients respond repetitively once the drug 
is re-administered. There is far more unknown than known and future basic studies should 
address these questions.      
 70 
The results of our study revealed that 66% and 29% of paediatric and adult CD patients 
respectively became IFX dependent. To date, two studies of children cohorts have been 
published evaluating the frequency of IFX dependency and reported that 42% and 56% of 
children developed IFX dependency (136;139). Our finding of 66% of dependent children is in 
agreement with the high frequency of this response phenotype observed in the previous studies. 
However, the results of adult population indicate a lower frequency of IFX dependency 
compared with children cohorts. The potential explanation could be that paediatric IBD seems to 
have different phenotype than adult onset-disease with more extensive involvement and 
aggressive disease course (201;202). We can only speculate that the differences between 
paediatric and adult cohorts might be due to the different natural disease courses in these two 
populations.  
Significantly more Danish than Czech patients developed IFX dependency. The significant 
difference in treatment regimes between the two countries seems to be the probable cause of this 
observation. Nevertheless, the treatment policy which was discussed prior to study start assumed 
to be similar in both cohorts. Furthermore, if the potential non-availability of IFX with 
subsequent more induction regimes only was the reason of low frequency of IFX dependency in 
Czech cohort, one would expect that patients with a good initial response and early relapse after 
IFX stop but without IFX re-introduction would have been considered non-responders as per 
definition. However, no significant difference in  non-responders was observed, in contrast 
Czech patients maintained significantly more prolonged response than Danish ones (data not 
shown). Furthermore, Czech patients had lower cumulative probability of surgery after IFX start 
than Danish patients. We thus hypothesize that other factors such as potential referral centre bias 
regarding disease severity at IFX start could contribute to this observation.  
In children cohort, inflammatory disease behavior was associated with significantly better long-
term outcome compared to complicated disease. This is in agreement with the finding that 
surgery naïve patients prior to IFX start, assumed to have mainly non-stricturing/non-penetrating 
disease, were more likely to become prolonged responders or IFX dependent.  
Children with perianal fistula at IFX start had higher probability to become IFX dependent. 
Perianal disease has varied complexity and severity with an impact on therapeutic result and 
deep and permanent healing of all tracks is an important assumption of sustained response (203). 
The superficial healing or premature closure with remaining deep tracks leading to early and 
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recurrent relapses might partly explain our finding. Contrary to our result, the national paediatric 
study from Netherlands reported higher rate of IFX dependency in children without fistulas than 
in those with fistulizing disease (136). No relevant clinical predictor was identified in adult 
cohort. 
No genetic predictor was identified in paediatric cohort, while two variants were found in our 
study of adult population. In Danish patients, the presence of G allele of LTA c.207 A>G variant 
was associated with better long-term IFX outcome. Taken in account the results by Taylor et al. 
(204) who reported a certain haplotype of lymphotoxin alpha (LTA) to be responsible for a 
decreased response to IFX in CD, this could suggest a possible role of LTA variants in prediction 
of IFX outcome. However, this finding could not be replicated in the Czech cohort. In Czech 
patients, we revealed an association of T allele of CASP9 c.93 C>T variant with IFX dependent 
phenotype. Similarly, Hlavaty et al. (205)  have previously reported an association of TT 
genotype of CASP9 c.93 C>T variant with positive short-term response to IFX. No such 
association was found in Danish patients, despite the same frequency of this variant in both 
background populations. 
The TNF–308 A>G variant has been shown to influence the production of TNF-α (206) and to be 
associated with disease activity of CD (206;207). Nevertheless, no association of variants within 
genes encoding TNF-α or its receptor with IFX outcome has been proven in previously published 
studies (208;209), nor has our study proven it. FASLG c.-844 C>T variant of FasL/Fas system 
involved in apoptosis has been shown to have an influence on IFX outcome
 
(205), however our 
study failed to reveal any association of this variant with IFX response.  
Patients with prolonged response as well as IFX dependent individuals were shown to have 
lower cumulative probability of surgery compared to non-responders. Of note is that IFX 
dependent children had even significantly lower risk of surgery than those with prolonged 
response. The question whether biological therapy is able to modify the disease course and 
decrease the need for surgical interventions is still unclear. So far, there is only a little evidence 
that IFX might reduce the surgery rate (210-213). Our findings show that the need for surgery in 
both prolonged responders and IFX dependent patients may be at least postponed if not avoided.      
The major limitation of our IFX dependency studies is the retrospective character bearing the 
risk of data validity and misinterpretation. The study design also precluded assessment of other 
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factors of clinical interest such as smoking or disease activity. On the other hand retrospective 
studies provide reflection of the everyday clinical practice and thus have their role in evidence.  
Furthermore, the treatment regimes used in the two countries were different. This happened 
despite the fact that the treatment strategy was discussed prior to study start and seemed to be 
similar. Nevertheless, when finally analyzing the data we found that that there was a difference 
in treatment approach between the countries. Regarding genetic analyses, the study populations 
were quite small (mainly in paediatric cohort) which could be a reason that possible associations 
were not detected. Moreover, no adjustment for other confounders (such as smoking, disease 
related characteristics) was performed due to relatively small numbers of subjects. Therefore our 
results should be interpreted with caution and larger independent cohort is needed to confirm or 
disprove these findings. 
 
Dependent response phenotype has been also described for another drug used in the treatment of 
IBD, 5-ASA. This phenotype has been defined and described for the first time in our study. 
Efficacy of 5-ASA in treatment of CD is considerably lower compared to corticosteroids or IFX 
with the number needed to treat of 10 and 13 for induction and maintenance of remission (214). 
Despite this fact the results of our study demonstrated that there is a group of CD patients with a 
nice response to 5-ASA preparations. Of 165 patients who started on 5-ASA monotherapy 59% 
obtained long-term benefit (prolonged response or 5-ASA dependent) with 23% being 5-ASA 
dependent. 5-ASA dependent patients contrary to prolonged responders represented a specific 
group having a relapse of the disease repetitively responding to 5-ASA and thus confirming 
efficacy of the drug. The results of our study may seem too favourable; however, it has to be 
emphasized that a selected group was analysed (31% of all CD patients treated at Herlev 
hospital). Thus, the total number of CD patients with a long-term benefit of 5-ASA was not high, 
as one would expect. Nevertheless, 5-ASA preparations are one of the safest therapeutics used in 
IBD and if 5-ASA was not used in CD any longer these patients would have to be treated with 
other, more potent but also more toxic anti-inflammatory agents.   
The role of 5-ASA in CD was also demonstrated in a recent retrospective study from Germany 
(215). In that study 103 newly diagnosed CD patients from 12 gastroenterology centres, 
followed-up for at least 12 months were included. The authors observed that 15% of all patients 
had a mild disease course treated only with mesalazine therapy and of them almost 50% were 
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maintained only on 5-ASA up to 48 months without need of “stronger” anti-inflammatory 
agents. Older age at diagnosis, lower inflammatory activity expressed by lower C-reactive 
protein and lack of severe endoscopic findings were associated with this mild disease course 
(215). 
In our study, female gender was identified as a predictor of better long-term response to 5-ASA. 
This might be explained by the findings of previous study reporting lower adherence with 
maintenance 5-ASA medication in males (216). Focusing on 5-ASA dependent phenotype, 
patients with longer disease duration were more likely to become dependent. Theoretically, this 
finding may be rather a reflection of a very mild disease phenotype. This speculation might be 
also supported by our results of significantly lower cumulative probability of surgery in 5-ASA 
dependent patients compared to non-responders, which was not observed in case of prolonged 
responders.  
Our study of 5-ASA dependency has several limitations. First limitation is the retrospective 
character carrying the risk of misinterpretation of the treatment response which was based on 
medical records only. Secondly, the adherence to 5-ASA could not be assessed and was assumed 
only by the record that the patient was taking the drug. Furthermore, other factors such as 
smoking which might have had an impact on disease course were not assessed due to study 
design. Finally, different 5-ASA preparations and doses were used with a possible impact on the 
results, although one would expect worse treatment outcome in case of low doses or unsuitable 
drug forms. 
Contrary to CD, 5-ASA works well in mild to moderate UC (164;165;172-174). The reason for 
this difference is unknown and is likely to be in the different pathophysiologic origin of the 
diseases. 5-ASA seems to exert its anti-inflammatory efficacy by local effect on colonic mucosa 
irrespective of systemic serum concentrations (217;218). There is a relationship between 
mucosal 5-ASA levels and endoscopic activity with higher 5-ASA tissue concentrations being 
associated with better mucosal healing (217;218). Theoretically, the relative infectivity of 5-ASA 
in CD compared to UC might be based on the fact that while UC affects mucosa only, CD is a 
transmural disease involving also deeper layers of the bowel. Nevertheless, as shown by our and 
other studies there are some patients who benefit from 5-ASA having probably very mild disease 
inflammatory activity.    
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Similarly to anti-TNFs and 5-ASA, response to corticosteroids varies among the individuals. 
Over 80% of IBD patients respond primarily to corticosteroid therapy, either completely or 
partially (78).  Nevertheless, of primary responders a proportion of patients lose their response, 
while 22% to 36% of adult individuals with IBD become steroid dependent (78;137).        
So far, several mechanisms of this variable sensitivity to corticosteroids have been proposed, 
nevertheless the exact mechanism is still not known. Based on complexity of corticosteroid 
action the responsiveness to the drug may be impacted at several levels of corticosteroid 
signalling.  
Intracellular receptor for corticosteroids has been proposed as the first place responsible for 
steroid resistance. To date, several polymorphisms in gene encoding the receptor have been 
described with only a few seem to be relevant.  Three polymorphisms - TthIIII, ER22/23EK and 
GR-9β - have been identified as potentially associated with reduced sensitivity to endogenous 
and exogenous glucocorticoids (81). Nevertheless, their role with regard to corticosteroid 
response in IBD or other diseases has not been largely studied yet and a study on paediatric IBD 
patients failed to show any association between ER22/23EK polymorphism and response to 
corticosteroids (219). Inversely, a variant of receptor gene BclI has been linked to an increased 
sensitivity to corticosteroids (81). In an Italian study of IBD children (219), a significant 
association between BclI polymorphism and corticosteroid response was found with a higher 
frequency of mutated genotype in children with corticosteroid dependency than in steroid 
responsive non-dependent individuals (OR 5.94, 95%CI: 1.23-28.6). Glucocorticoid receptor is a 
heterocomplex existing in a complex with several protein components which keep receptor in 
optimal conformation for ligand binging (81). Impairment in these components has been found in 
individuals with steroid resistant asthma, sclerosis multiplex and idiopathic nephritic syndrome 
(81). Their association with corticoresistant IBD has not been studied yet (81). 
Translocation of corticosteroid-receptor complex to nucleus is mediated via specific nuclear 
transport factors – importins (81). Their alteration thus seem to be other locus minoris for 
steroids resistance although their role in corticosteroid response in IBD or other diseases has 
been studied only a little or not at all and needs further investigation (81).  
There is evidence that several cytokines influence effect of corticosteroids trough interference 
with the corticosteroid signalling pathway. For example, TNFα and IL-2 have negative impact on 
steroid action while IL-10 acts inversely (81). Furthermore, higher levels of TNFα and other pro-
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inflammatory cytokines have been described in mucosa of UC patients resistant to 
corticosteroids (118). Interestingly the A allele of G-308A variant of TNF gene which has been 
linked to an increased production of TNFα has been reported to be associated with steroid 
dependency in a population of CD patients (220). Furthermore, in another study carries of A 
allele of G-308A variant have been found to be more likely resistant to corticosteroids than 
individuals with GG genotype (OR 0.29, 95%CI: 0.08-0.98) (221). No association with steroid 
dependency was revealed in that study.  
Finally, the role of P-glycoprotein and the polymorphisms of its encoding gene MDR1 (multi 
drug resistance) have been studied with regard to response to corticosteroids (81;82;222). P-
glycoprotein serves as a cell pump which transports xenobiotics and different drugs out of the 
cells and thus may decrease their efficacy (81;82;222). While some studies have shown an 
association between MDR1 variants and corticosteroid response, other failed to confirm these 
findings (221;223-225).   
 
Drug dependency, connected with corticosteroids mainly, used to be considered negatively. 
However, it can be also a positive response outcome which may offer the patient some benefits. 
To decide its implication in disease prognosis, the safety and the efficacy of the drug have to be 
evaluated.  
Corticosteroids are strong anti-inflammatory agents with a high response rate and prompt onset 
of clinical effect (214). However, their use is associated with a wide range of serious adverse 
events including growth impairment in children (79). Moreover, in long-term perspectives 
corticosteroids seem to carry relatively high risk of surgery as 27%-38% of CD patients have 
been reported to undergo surgery within one year after drug cessation (137;143). More 
favourable results, however, may be found in recent paediatric population-based study from 
Denmark (138). The study showed that despite the high frequency of steroid dependency in their 
cohort (37% in CD and 49% in UC), the cumulative risk of surgery within the first year after 
steroids start was relatively low for both CD and UC (11.5% and 7.8% respectively) with  no 
difference between steroid dependent and non-dependent individuals. This finding is probably 
related to high rate of early introduced immunomudulators in this cohort (80%). Similar 
observations can be found also in other recent paediatric studies (141;226).  
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IFX shows similar short term efficacy as corticosteroids (214) but contrary to steroids IFX seems 
to have also long-term benefit in terms of disease activity control, reduced number of 
hospitalizations and perhaps also decreased need for surgery (163;211-213;227). Thus, from this 
point of view and also based on results of our studies, IFX dependency seems to be a disease 
phenotype with a good prognosis.  
Despite the evident clinical benefit of IFX, the treatment, mainly in long-term term use is 
associated with certain drawbacks. As already mentioned, the potential complications might be 
very serious and life-threatening (157;158;160), further there is an increasing evidence of 
probably immunopathological complications induced by biological preparations such skin and 
joint problems (199;228;229). Moreover, there is no data about the consequences of the long-
standing use of IFX yet. No less, the therapy is very expensive and represents a big economic 
burden (162;163). Therefore, identification of IFX dependent individuals may be very useful in 
clinical management. It may prevent ”overtreatment” of non-dependent individuals, and thus 
limit potential toxicity in these patients. Furthermore, overall cost-effectiveness of IFX treatment 
may be improved. 
5-ASA in treatment of CD compared to UC has only limited efficacy. But as obvious from our 
and also other studies, there is a population of CD patients with a very mild disease course which 
can be managed just by 5-ASA preparations. 5-ASA dependent individuals seem to represent a 
specific group among these patients maintaining disease remission rather by 5-ASA than natural 
disease evolution which probably plays more or less important role in patients with prolonged 
response. Since 5-ASA preparations have a very low toxicity, 5-ASA dependency might be seen 
as a favourable condition with a good prognosis. Self-management of the disease has been 
proposed to optimize patient adherence to therapy and reduce the healthcare costs (230;231). 
Recently, a very interesting study has been published dealing with web-based self-treatment of 
UC patients with 5-ASA preparations (14). The study has shown the benefit of this approach 
compared to “classic” one in terms of reduction of relaps duration, cost-effectiveness, 
improvement of treatment adherence and quality of life. 5-ASA preparations with their good 
safety profile would represent an ideal drug for disease self-management which might be a 
suitable therapeutic approach for 5-ASA dependent individuals.  
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Drug dependency is more than just a simple response pattern; it is a specific disease phenotype 
with a certain prognostic value which depends on particular drug. Hence, it can be used as a 
helpful prognostic marker in everyday clinical management. Early identification of dependent 
individuals might prevent negative consequences of steroid therapy; avoid “unnecessary” use of 
infliximab in non-dependent individuals, lead to better treatment cost-effectiveness and limit 
















In these studies, IFX dependency in children with CD was assessed and for the first time IFX 
dependency in adult cohort with CD and 5-ASA dependency in CD patients were studied.  
The frequency of IFX dependency in children was found to be similarly high as in the previous 
paediatric studies, whereas a lower rate was observed in adult cohort. In children, perianal 
disease and no bowel surgery prior to IFX start were predicative of IFX dependency, while 2 
genetic variants LTA c.207 A>G and CASP9 c.93 C>T were associated with IFX outcome in 
adult population. Future studies, however, have to assess the relevance of these findings.  
Probably, the most relevant for the clinicians and CD patients was a finding of a significant 
decrease in surgical rate after IFX initiation which was observed in both prolonged responders 
and IFX dependent patients, in paediatric as well as in adult cohort.  
5-ASA therapy was shown to be efficacious in a subgroup of patients with CD. Fifty-nine 
percent of included patients had long-term benefit of 5-ASA and 23% of them were 5-ASA 
dependent. Women were more likely to have a good response to 5-ASA than men. 5-ASA 
dependent patients were characterized by a very mild disease course reflected by the lowest 
surgical rate.   
Drug dependency is a specific disease phenotype which determines patient´s prognosis. Hence, it 
may be used as a prognostic marker when deciding for treatment management. Whereas 
corticosteroid dependency itself has a negative impact on disease course, IFX and 5-ASA 
dependency seem to have a good prognosis. Prediction of the clinically relevant dependent 
patient still needs to be explored. The developing web-based treatment programmes for patient 
self-management based on individual disease course might be an option in the future. 
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9 PERSPECTIVES 
The use of ”dependency definitions” in clinical practice is problematic. One reason is their 
heterogeneity. The other reason are the over time changing treatment recommendations. 
Currently, immunomodulators are introduced earlier to avoid corticosteroid dependency and IFX 
is indicated as long-term maintenance therapy in all patients responding to it (79;88). Thus, the 
frequency of drug dependency may be biased. Further, the doctor preference and economical 
possibilities have to be also considered. Hence, it is important that the definitions also reflect 
these changes in clinical practice and are adjusted according to the actual requirements.  
 
Early identification of mainly IFX dependent individuals may seem to be challenging as IFX is 
recommended as long-term maintenance treatment in all individuals responding to induction 
therapy. The developing web based treatment systems which offer patients self management 
according to their individual needs provide a good picture of the patient´s disease course and 
may thus in the future help to identify dependent individuals (15). 
 
Future studies should assess the frequency of IFX and 5-ASA dependency also in UC patients. 
Furthermore, other drugs used in IBD such as adalimumab and azathioprine should be studied 
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